CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a…
CytoSorbents Reports Second Quarter 2026 Financial Results,
Recent Business Highlights, and Regulatory Update
Highlighting Four Independent Drivers of Shareholder Value
PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the
treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood
purification, today reported financial results for the second quarter ended June 30, 2026, recent
business highlights, and provides a regulatory update.
Second Quarter 2026 Financial Results
• Revenue was $9.6 million, unchanged from a year ago.
• Gross margin improved to 73% in the quarter, up sequentially from 69% in Q1 2026
and from 71% a year ago.
• Operating loss improved by 27% to $2.6 million versus $3.6 million in Q2 2025.
• Net loss was $4.4 million or $0.07 per share, compared to net income of $1.9 million
or $0.03 per share in Q2 2025, due primarily to the non-cash impact of changes in
foreign currency translations year over year.
• Adjusted net loss, which excludes the impact of non-cash changes in foreign currency
translations and non-cash stock compensation, improved by 22% to $2.8 million or
$0.05 per share, compared to an adjusted net loss of $3.7 million or $0.06 per share
in Q2 2025.
• Adjusted EBITDA loss, which also excludes the impact of non-cash changes in foreign
currency translations and non-cash stock compensation improved by 38% to $1.6
million compared to a loss of $2.6 million in Q2 2025.
• Total cash, cash equivalents, and restricted cash was approximately $5.9 million on
June 30, 2026, compared to $6.3 million at March 31, 2026.
• Total cash burn in the second quarter was reduced to $0.4 million, inclusive of
approximately $0.2 million in restructuring-related payments.
“Second quarter revenue performance was led by strong growth in our distributor and strategic
partner territories, as well as direct sales outside of Germany, but offset by a decline in sales in
Germany attributed to a smaller, but more focused sales force. We are encouraged by the
improved productivity and sales execution of this team and expect to add three to five new sales
representatives through early 2027 to restore full country coverage,” stated Dr. Phillip Chan,
Chief Executive Officer of CytoSorbents. “We are also pleased with the continued improvements
in our operating execution in the quarter, including an increase in gross margins to 73%, a 27%
reduction in operating loss, a 38% improvement in adjusted EBITDA loss, and importantly, a
reduction in operating cash burn to $200,000 excluding restructuring payments. These gains
reflect disciplined execution across our organization, including manufacturing optimization,
improved working capital management, commercial execution, and tighter cost controls. As a
result, we believe we remain on track toward our objective of achieving operating cash flow
breakeven in the second half of this year.
Over the past couple of years, our priorities have been clear. We have needed to strengthen the
financial foundation of the Company, improve commercial and operating execution, advance our
regulatory programs, and position the business for sustainable long-term growth. During the
second quarter, we continued making meaningful progress against each of these objectives.
While we are not yet where we want to be, we believe CytoSorbents today is better positioned
for success than it was a year ago.
Four Independent Value Drivers
Looking ahead, we believe CytoSorbents has strong value creation opportunities. We believe we
have four independent value drivers over the next six to eighteen months and that each has the
potential to strengthen the business and create meaningful long-term shareholder value by
reducing risk, expanding profitability, opening new markets, and unlocking strategic value.
First Value Driver: Achieving Operating Cash Flow Breakeven
Our first value driver is reducing financial risk by achieving sustainable operating cash flow
breakeven.
Over the past year, we have focused relentlessly on improving the economics of our business.
Product gross margin improved to 73% during the second quarter through manufacturing
optimization, improved sourcing, and production efficiencies. We also lowered our cash burn
through improved commercial execution, collections, and working capital management while
continuing to streamline our organization. Since September 2025, we have reduced our
workforce by approximately 23%, creating a leaner and more focused company.
As a result, operating cash burn declined to approximately $200,000 during the quarter,
excluding restructuring charges, representing another meaningful step toward operating cash
flow breakeven.
We believe this milestone is important because it fundamentally changes the Company's financial
profile. Every dollar of operating cash burn eliminated reduces future financing needs,
strengthens our balance sheet, increases strategic flexibility, and allows a greater proportion of
future growth to accrue to shareholders. Although important work remains, we believe the
progress achieved over the past year demonstrates that this strategy is working."
Second Value Driver: Returning the CytoSorb Business to Sustainable, Profitable Growth
Our second value driver is returning our core CytoSorb business to sustainable, profitable growth.
Although overall revenue growth remains modest today, the majority of the business did well
during the second quarter, with 16% growth in distributor and strategic partner sales despite
geopolitical disruption in the Middle East, and 9% growth in direct sales outside of Germany, but
offset by a 24% decrease in Germany sales, attributed to a smaller, but more focused sales force
following our restructuring. In Germany, we have significantly improved the efficiency of our
smaller commercial organization and expect to drive a return to growth in the country by
regaining full territory coverage through the addition of three to five new sales representatives
through early 2027.
At the same time, our messaging and training of treating the “Right Patient, at the Right Time,
with the Right Dose” continues to resonate with customers. This is partially evident in the
increasing customer adoption of our PuriFi® pump platform and HotSwap® technology which
have been received very well. These technologies simplify therapy delivery, encourage earlier
and more intensive intervention, and promote more consistent utilization of CytoSorb.
We believe these and other initiatives, particularly the operational investments and commercial
restructuring completed over the past year, have positioned us for greater sales effectiveness
that can strengthen both clinical adoption and long-term profitable growth of the franchise.
Third Value Driver: Opening the U.S. Market Through DrugSorb-ATR
Our third value driver is obtaining FDA marketing approval for DrugSorb-ATR and opening what
we believe represents one of the Company's most important long-term growth opportunities.
DrugSorb-ATR addresses a significant unmet need in cardiac surgery by removing commonly
prescribed blood thinners during cardiopulmonary bypass for patients requiring urgent surgery.
With the positive results of the STAR-T trial in CABG patients now published and the growing
body of real-world evidence using our therapies for the anti-platelet drug Brilinta® and the direct
oral anticoagulants, Eliquis® and Xarelto®, we are confident in the worldwide potential of our
technologies for this application. In the U.S. and Canada alone, with future approval, we believe
this represents an initial market opportunity of approximately $500 million to $1 billion, with the
potential to expand substantially as additional surgical indications are pursued.
During August, we have two important FDA pre-submission meetings scheduled. The first is to
discuss options to generate additional mechanistic data requested by FDA for our Brilinta®
program. Following this meeting, we intend to finalize and confirm the testing protocol with FDA,
which may require an additional meeting with the Agency. Once finalized, we anticipate
completing the required testing, and submitting a new De Novo application in early 2027 that
will include these data and new real-world clinical evidence analyses involving four times the
number of coronary artery bypass graft (CABG) patients on Brilinta® treated with DrugSorb-ATR,
compared to the original STAR-T trial.
In the second scheduled meeting, we will present our data to the FDA supporting a potential
parallel De Novo submission for DrugSorb-ATR in patients receiving direct oral anticoagulants, or
DOACs, and discuss what additional information, if any, the Agency believes is necessary.
We believe these meetings will provide additional clarity toward FDA marketing authorization.
Successful marketing approval would establish a second commercial franchise alongside our
international CytoSorb business, open access to the world's largest healthcare market, further
validate our adsorption technology platform, increase our gross margins and potential
profitability, and create opportunities for future expansion.
Fourth Value Driver: Unlocking the Strategic Value of HemoDefend-BGA
Our fourth value driver is realizing the strategic value of HemoDefend-BGA - a technology that
we believe is not fully reflected in today's valuation.
Developed with approximately $16 million of prior non-dilutive U.S. government funding,
HemoDefend-BGA is a sophisticated blood filter designed to remove anti-A and anti-B antibodies
from plasma and platelet products, enabling the production of ‘universal’ blood products that
can be transfused regardless of recipient blood type - without electricity, capital equipment, or
complex processing.
The technology has the potential to simplify blood inventories, reduce waste, lower costs, and
improve access to life-saving blood products. Leading blood centers have helped to evaluate and
validate the technology, and we believe its commercial potential extends well beyond today's
blood banking model.
As one example, imagine the simplification and cost savings to hospital blood banks from
currently maintaining 4 types of plasma (A, B, AB, O) and 4 types of platelets to now just 1
universal plasma and 1 universal platelet product. Or picture a future where every ambulance,
first responder, or military vehicle around the world carries freeze-dried universal plasma on
board - without refrigeration, without the need to blood type, and ready for immediate
transfusion to patients suffering severe trauma and life-threatening hemorrhage. We believe
HemoDefend-BGA has the potential to help make that future possible.
Over the past year, we completed product development, and in July 2026 we received
constructive FDA feedback regarding our anticipated clinical pathway following a pre-submission
interaction with the Agency. In addition, we continue to have encouraging discussions with U.S.
government agencies regarding potential non-dilutive funding for future clinical development.
While our immediate priorities remain achieving operating cash flow breakeven, growing the
CytoSorb franchise, and advancing DrugSorb-ATR, we believe HemoDefend-BGA represents a
valuable strategic asset with multiple potential pathways to create shareholder value, including
commercial partnerships, licensing opportunities, government funding, or other strategic
alternatives.
Looking Ahead: Four Independent Value Drivers. One Uncommon Value.
Taken together, these four value drivers represent multiple independent opportunities to create
value over the next 6 to 18 months.
• The first reduces financial risk by expanding operating margins, and achieving
operating cash flow breakeven
• The second returns our core CytoSorb business to consistent, profitable growth,
• The third opens the U.S. market and establishes what we believe can become a second
major commercial franchise
• And the fourth unlocks the value of a highly differentiated blood purification platform
with meaningful strategic optionality
We believe each of these initiatives has the potential to independently strengthen our business
and increase shareholder value. Together, they have the potential to fundamentally transform
CytoSorbents into a stronger, more profitable, and more diversified medical technology
company.
Dr. Chan concluded, “Although more work remains, we believe our accomplishments over the
past several quarters have stabilized the company and have positioned it for this next phase,
where our entire organization remains intensely focused on disciplined execution. In the near
future, we intend to regain compliance with our Nasdaq listing requirements, broaden the
awareness of our Company and our four separate value drivers, and secure the Company
financially. We appreciate our shareholder’s support and look forward to updating them as we
continue to make progress on each of these important objectives.”
Second Quarter 2026 Earnings Conference Call
CytoSorbents’ management will host a live conference call, presentation webcast, and a
question-and-answer session with the following information:
Date: Thursday, August 6, 2026
Time: 4:30 PM ET
Live webcast link: https://app.webinar.net/v62381bx4na
It is recommended that participants join approximately 10 minutes prior to the start of the call.
An archived recording of the conference call will be available under the Investor Relations section
of the Company’s website at https://ir.cytosorbents.com/
About DrugSorb-ATR
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal
system, an investigational device based on an equivalent polymer technology to CytoSorb, to
reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It
has received two U.S. Food and Drug Administration (“FDA”) Breakthrough Device Designations:
one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants
(DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent
cardiothoracic procedures.
The Company continues to actively pursue regulatory approval of DrugSorb-ATR with the FDA
and expects to pursue regulatory approval in Canada with better visibility from the FDA.
DrugSorb-ATR is not yet granted or approved in the United States and Canada, respectively.
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, we use the non-GAAP financial
measures of EBITDA, which measures earnings before interest, income taxes, depreciation and
amortization, and Adjusted EBITDA which further excludes non-cash stock compensation
expense, the gain or loss of foreign exchange translation, and restructuring charges. We also use
the non-GAAP financial measures of Adjusted Net Income or Loss and Adjusted Net Income or
Loss Per Share which excludes non-cash stock compensation expense, the gain or loss of foreign
exchange translation, and restructuring charges from Net Loss and Net Loss Per Share,
respectively. These non-GAAP measures are not based on any comprehensive set of accounting
rules or principles and should not be considered a substitute for, or superior to, financial
measures calculated in accordance with GAAP and may be different from non-GAAP measures
used by other companies. In addition, these non-GAAP measures should be read in conjunction
with our financial statements prepared in accordance with GAAP. The reconciliations of the non-
GAAP measures to the most directly comparable financial measures calculated and presented in
accordance with GAAP should be carefully evaluated. We use these non-GAAP financial measures
for financial and operational decision-making and as a means to evaluate period-to-period
comparisons. We believe that these non-GAAP financial measures provide meaningful
supplemental information regarding our performance and that both management and investors
benefit from referring to these non-GAAP financial measures in assessing our performance and
when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial
measures are useful to investors because (1) they allow for greater transparency with respect to
key metrics used by management in its financial and operational decision-making and (2) they
are used by investors and the analyst community to help them analyze the performance of our
business, the Company’s cash available for operations, and the Company’s ability to meet future
capital expenditure and working capital requirements. For a reconciliation of non-GAAP financial
measures to the most comparable GAAP measure, see the reconciliation included in the financial
tables. All non-GAAP adjustments are presented pre-tax.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the
intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary
blood purification technologies are based on biocompatible, highly porous polymer beads that
can actively remove toxic substances from blood and other bodily fluids by pore capture and
surface adsorption. Cartridges filled with these beads can be used with standard blood pumps
already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT,
extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is
repeatedly recirculated outside the body, through our cartridges where toxic substances are
removed, and then back into the body. CytoSorbents’ technologies are used in a number of broad
applications. Specifically, two important applications are 1) the removal of blood thinners during
and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of
inflammatory agents and toxins in common critical illnesses that can lead to massive
inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for
example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and
pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or
failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal
failure. In these diseases, the risk of death can be extremely high, and there are few, if any,
effective treatments.
CytoSorbents’ lead product, CytoSorb
®
, is approved in the European Union and distributed in
over 70 countries worldwide, with more than 300,000 devices used cumulatively to date.
CytoSorb was originally launched in the European Union under CE mark as the first cytokine
adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in
clinical conditions such as liver disease and trauma, respectively, and
for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also
received FDA Emergency Use Authorization in the United States for use in adult critically ill
COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved
or cleared in the United States.
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal
system, an investigational device based on an equivalent polymer technology to CytoSorb, to
reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It
has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and
another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a
cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively
pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory
approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted
or approved in either the U.S. or Canada.
The Company has numerous marketed products and products under development based upon
this unique blood purification technology protected by many issued U.S. and international
patents and registered trademarks, and multiple patent applications pending, including ECOS-
300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™,
DrugSorb™, ContrastSorb, PuriFi®, HotSwap®, and others. For more information, please visit the
Company’s website at https://ir.cytosorbents.com/ or follow us on Facebook and X.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform Act of 1995. These forward-
looking statements include, but are not limited to, statements about our plans, objectives, future
targets and outlooks for our business, representations and contentions, and the outcome of our
regulatory submissions, and are not historical facts and typically are identified by use of terms
such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“potential,” “continue” and similar words, although some forward-looking statements are
expressed differently. You should be aware that the forward-looking statements in this press
release represent management’s current judgment and expectations, but our actual results,
events and performance could differ materially from those in the forward-looking statements.
Factors which could cause or contribute to such differences include, but are not limited to, our
restructuring of our direct sales team and strategy in Germany, ability to successfully
obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to reduce
costs, optimize operations, and achieve cash-flow break-even in the second half of 2026, our
ability to appropriately finance the Company, and the risks discussed in our Annual Report on
Form 10-K, filed with the SEC on March 30, 2026, as updated by the risks reported in our
Quarterly Reports on Form 10-Q, and in the press releases and other communications to
shareholders issued by us from time to time which attempt to advise interested parties of the
risks and factors which may affect our business. We caution you not to place undue reliance upon
any such forward-looking statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events, or
otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
U.S. Company Contact:
Peter J. Mariani, Chief Financial Officer
305 College Road East
Princeton, NJ 08540
[email protected]
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in thousands, except share data)
June 30,
December 31,
2026
2025
(unaudited)
ASSETS
Current Assets:
Cash and cash equivalents
$ 4,413
$ 6,249
Accounts receivable, net of allowances of $421 and $164 as of
June 30, 2026 and December 31, 2025
6,786
7,550
Inventories - net
3,686
5,281
Prepaid expenses and other current assets
852
1,554
Total current assets
15,737
20,634
Property and equipment - net
7,172
7,823
Restricted cash
1,522
1,522
Right-of-use asset
10,612
10,924
Patents - net
2,864
3,226
Other assets
53
53
Total assets
$
37,960
$
44,182
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities:
Accounts payable
$ 2,002
$ 2,869
Accrued expenses and other current liabilities
7,283
6,299
Lease liability – current portion
589
541
Current maturities of long-term debt, net of debt discount
14,149
—
Total current liabilities
24,023
9,709
Lease liability, net of current portion
11,596
11,903
Long-term debt, net of current portion and debt discount
3,092
16,667
Total liabilities
38,711
38,279
Commitments and Contingencies
Stockholders’ equity (deficit)
Preferred Stock, par value $0.001, 5,000,000 shares authorized; no shares
issued and outstanding as of June 30, 2026 and December 31, 2025
—
—
Common Stock, par value $0.001, 100,000,000 shares authorized;
62,842,748 and 62,804,305 shares issued and outstanding as of
June 30, 2026 and December 31, 2025 respectively
63
63
Additional paid-in capital
321,936
321,024
Accumulated other comprehensive loss
(996)
(2,977)
Accumulated deficit
(321,754)
(312,207)
Total stockholders’ equity (deficit)
(751)
5,903
Total liabilities and stockholders’ equity (deficit)
$ 37,960
$ 44,182
See accompanying notes to condensed consolidated financial statements.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(in thousands, except share and per share data)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenue, net $ 9,633 $ 9,617 $ 18,497 $ 18,344
Cost of goods sold
2,584
2,803
5,318
5,323
Gross profit
7,049
6,814
13,179
13,021
Operating expenses
Research and development, net of grant income
1,453
1,262
2,478
2,924
Selling, general and administrative
7,964
9,167
16,073
17,599
Restructuring
270
—
310
—
Total operating expenses
9,687
10,429
18,861
20,523
Loss from operations
(2,638)
(3,615)
(5,682)
(7,502)
Other income (expense)
Interest expense, net
(868)
(616)
(1,726)
(1,221)
Gain (loss) on foreign currency transactions
(911)
6,178
(2,139)
9,192
Total other income (expense), net
(1,779)
5,562
(3,865)
7,971
Net income (loss)
$ (4,417)
$ 1,947
$ (9,547)
$ 469
Basic net income (loss) per common share
$ (0.07)
$ 0.03
$ (0.15)
$ 0.01
Diluted net income (loss) per common share
$ (0.07)
$ 0.03
$ (0.15)
$ 0.01
Weighted Average Shares of Common Stock
Outstanding
Basic
62,806,694
62,608,598
62,772,761
61,675,447
Diluted
62,806,694
67,166,377
62,772,761
66,255,298
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax
1,105
(5,476)
1,981
(8,212)
Comprehensive loss
$ (3,312)
$ (3,529)
$ (7,566)
$ (7,743)
See accompanying notes to condensed consolidated financial statements.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
(UNAUDITED)
(in thousands, except share data)
Accumulated
Additional
Other
Common Stock
Paid-In
Comprehensive
Accumulated
Stockholders’
Shares Par Value Capital Loss Deficit Equity (Deficit)
For the three months ended June 30, 2026
Balance as of March 31, 2026 (unaudited)
62,733,305
$ 63
$ 321,568
$ (2,101)
$ (317,337)
$ 2,194
Stock-based compensation
—
—
368
—
—
368
Common stock issued upon vesting of restricted stock
units, less shares withheld to cover taxes
109,443
—
—
—
—
—
Foreign translation adjustment
—
—
—
1,105
—
1,105
Net loss
—
—
—
—
(4,417)
(4,417)
Balance as of June 30, 2026 (unaudited)
62,842,748
$ 63
$ 321,936
$ (996)
$ (321,754)
$ (751)
For the six months ended June 30, 2026
Balance as of December 31, 2025
62,804,305
$ 63
$ 321,024
$ (2,977)
$ (312,207)
$ 5,903
Stock-based compensation
—
—
912
—
—
912
Reversal of excess RSU shares issued
(71,000)
—
—
—
—
—
Common stock issued upon vesting of restricted stock
units, less shares withheld to cover taxes
109,443
—
—
—
—
—
Foreign translation adjustment
—
—
—
1,981
—
1,981
Net loss
—
—
—
—
(9,547)
(9,547)
Balance as of June 30, 2026 (unaudited)
62,842,748
$ 63
$ 321,936
$ (996)
$ (321,754)
$ (751)
Accumulated
Additional
Other
Common Stock
Paid-In
Comprehensive
Accumulated
Stockholders’
Shares Par Value Capital Loss Deficit Equity
For the three months ended June 30, 2025
Balance as of March 31, 2025 (unaudited)
62,529,466
$ 63
$ 318,452
$ 1,516
$ (305,487)
$ 14,544
Stock-based compensation
—
—
571
—
—
571
Common stock issued upon vesting of restricted stock
units, less shares withheld to cover taxes
69,260
—
—
—
—
—
Shares issued for exercise of stock options
11,650
—
—
—
—
—
Foreign currency translation adjustment, net of tax
—
—
—
(5,476)
—
(5,476)
Net income
—
—
—
—
1,947
1,947
Balance as of June 30, 2025 (unaudited)
62,610,376
$ 63
$ 319,023
$ (3,960)
$ (303,540)
$ 11,586
For the six months ended June 30, 2025
Balance as of December 31, 2024
54,830,146
$ 55
$ 310,809
$ 4,252
$ (304,009)
$ 11,107
Stock-based compensation
—
1
1,390
—
—
1,391
Common stock issued upon vesting of restricted stock
units, less shares withheld to cover taxes
101,581
—
—
—
—
—
Shares issued for exercise of stock options
11,650
—
—
—
—
—
Issuance of common stock and warrants from rights
offerings, net of fees incurred
6,249,791
6
5,386
—
—
5,392
Issuance of common stock from exercise of warrants
1,417,208
1
1,438
—
—
1,439
Foreign translation adjustment
—
—
—
(8,212)
—
(8,212)
Net income
—
—
—
—
469
469
Balance as of June 30, 2025 (unaudited)
62,610,376
$ 63
$ 319,023
$ (3,960)
$ (303,540)
$ 11,586
See accompanying notes to condensed consolidated financial statements.
CYTOSORBENTS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(in thousands)
Six
Six
Months Ended
Months Ended
June 30,
June 30,
2026 2025
Cash flows from operating activities
Net income (loss)
$
(9,547)
$ 469
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization of debt discount
573
381
Amortization of patents
123
124
Depreciation and amortization
576
649
Amortization of right-of-use asset
53
72
Loss on abandoned patents
338
—
Write-off of inventory
—
253
Bad debt expense (recovery)
240
9
Stock-based compensation
912
1,391
Foreign currency transaction (gains) losses
2,139
(9,192)
Changes in operating assets and liabilities
Accounts receivable
377
257
Inventories
1,512
(925)
Prepaid expenses and other current assets
645
1,897
Other assets
1
—
Accounts payable and accrued expenses
313
(360)
Net cash used in operating activities
(1,745)
(4,975)
Cash flows from investing activities
Purchases of property and equipment
(25)
(39)
Disposals of property and equipment
85
—
Payments for patent costs
(99)
(140)
Net cash used in investing activities
(39)
(179)
Cash flows from financing activities
Cash for exercise of warrants, net
—
1,439
Proceeds from rights offering, net
—
5,392
Net cash provided by financing activities
—
6,831
Effect of exchange rates on cash
(52)
285
Net change in cash, cash equivalents, and restricted cash
(1,836)
1,962
Cash, cash equivalents, and restricted cash as of beginning of period
7,771
9,764
Cash, cash equivalents, and restricted cash as of end of period
$ 5,935
$ 11,726
Supplemental disclosure of cash flow information
Cash paid for interest
$ 1,215
$ 1,018
Supplemental disclosure of non-cash financing activities
Fair value of common stock warrants issued in connection with the rights offering
$ —
$ 556
See accompanying notes to condensed consolidated financial statements.
RECONCILIATION OF GAAP FINANCIAL MEASURES TO NON-GAAP FINANCIAL MEASURES
Net income (loss)$(4,417) $
1,947
$(9,547)
$
469
Depreciation and amortization expense
$351
$404 $699 $773
Income tax expense (benefit)$ - $ - $ - $ -
Interest expense (income)$868
$
616
$
1,726
$1,221
EBITDA – non-GAAP measure$(3,198)
$2,967
$
(7,122)
$2,463
Non-cash stock-based compensation expense
$368
$571 $912 $1,391
(Gain)/Loss on foreign currency transactions911 (6,178) 2,139 (9,192)
Restructuring270 -
310 -
Adjusted EBITDA – non-GAAP measure$(1,649) (2,640)
$(3,761)
$(5,338)
Net income (loss)$(4,417)
$1,947 $(9,547) $469
Non-cash stock-based compensation expense368 571
912 1,391
(Gain)/Loss on foreign currency transactions
$911 $(6,178) $2,139 $(9,192)
Restructuring270
Adjusted net loss – non-GAAP measure$
(2,868) $(3,660) $
(6,186)
$(7,332)
Weighted average common shares outstanding
Bas ic62,806,694 62,608,598
62,772,761
61,675,447
Dilu t ed
62,806,694 67,166,377 62,772,761 66,255,298
Basic net income (loss) per common share
$(0.07)
$
0.03 $(0.15) $0.01
Diluted net income (loss) per common share$(0.07) $0.03
$(0.15)
$0.01
Non-cash stock-based compensation expense - basic$0.01 $0.01
$0.01 $
0.02
Non-cash stock-based compensation expense -
d ilu t ed
$0.01
$0.01 $0.01 $0.02
(Gain)/Loss on foreign currency transactions - basic
$0.01 $(0.10) $0.03 $(0.15)
(Gain)/Loss on foreign currency transactions - diluted$0.01 $(0.09) $0.03
$
(0.14)
Adjusted net income (loss) per common share – basic
– non-GAAP measure
$(0.05) $(0.06) $(0.10) $(0.12)
Adjusted net income (loss) per common share –
diluted – non-GAAP measure
$(0.05)
$(0.05) $(0.10)
$(0.11)
Three Months EndedSix Months Ended
June 30,June 30,
(amounts, in thousands)
2026
202520262025